Published Date: 01 Mar 2024
14 percent less long-term CRC mortality and 16 percent fewer deaths overall are shown by a large Swedish study.
Read Full NewsA phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and toripalimab in patients with high-risk intrahepatic cholangiocarcinoma.
Hypertensive disorders of pregnancy, chronic hypertension, and obesity are the primary risk factors for severe maternal morbidity.
Cannabis use disorder has a bidirectional and clinically meaningful association with major depressive disorder, new research suggests.
A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic cancer.
Upadacitinib may improve self-reported sleep quality at 3 months in patients with rheumatoid arthritis, with sustained benefits seen over the long term.
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant sacituzumab govitecan plus pembrolizumab, the SURE-02 trial finds.
Research is limited, but what has been done shows a possible connection.
1.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
2.
More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.
3.
Adding SBRT to systemic therapy could boost outcomes for some locally advanced hepatocellular carcinoma patients
4.
Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma
5.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
1.
Unlocking the Mysteries of ICD 10 Code Normocytic Anemia
2.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
3.
Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer
4.
The Unseen Danger of Anal Cancer: How to Protect Yourself
5.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation